Connect
← Return to Hormone Therapy (ADT) when ArteraAI Test says it's not necessary
Discussion
Hormone Therapy (ADT) when ArteraAI Test says it's not necessary
Prostate Cancer | Last Active: 9 hours ago | Replies (27)Comment receiving replies
@tjnoffy neo is before. As far as prostate cancer goes even if ADT does not help it will not hurt. However, your overall health might decrease if you lose bone, muscle, and have low testosterone for the rest of your life. That is the case against ADT. As mentioned, you can take actions to minimize the negative effects while on ADT.
The arterAI test is saying that for your case short term ADT will not improve overall survival. arteraAI is a new test. What did they score you on the 10-year distance metastasis and what percent were you in the intermediate risk group (both on arteraAI report)? I take it you were ST-ADT Biomarker Negative. I do not believe the biomarker(s) used are published so it is hard to comment on accuracy with no history. Other than biopsy slides they have Gleason, PSA, and stage data so not a genetic test.
As far as risk of recurrence did you have a Decipher test from biopsy tissue (it provides recurrence risk)? What percentage was type 4 from biopsy (higher is usually higher risk of both recurrence and metastasis)? Are you going to get a Prostox std test (genetic) for long term radiation GI side effects (calibrated with photon radiation but will be correlated with Photons) risk)?
Replies to "@tjnoffy neo is before. As far as prostate cancer goes even if ADT does not help..."
@jim18 Some of what you're asking here I don't know. I'm drinking from a fire hose, as I'm sure everyone here has at the outset. Here is what I do know from the ArteraAI test:
10-YEAR RISK OF DISTANT METASTASIS: LOW group (not INTERMEDIATE), 2.4% risk
10-YEAR RISK OF PROSTATE CANCER SPECIFIC MORTALITY: 1.1%
COMPARISON OF THIS PATIENT TO THOSE IN SAME NCCN RISK GROUP: 28th percentile
ST-ADT BIOMARKER: Negative
Looking at the drawn map of the biopsy, two of 13 biopsy sites were Gleason 7 (4+3), one was Gleason 7 (3+4)
I don't see any indication of a Decipher test, and a Prostox Std test has not been mentioned.
Connect
@jim18 While I agree with you that there might be no difference in ‘long term outcomes’ - which is survivability vs lethal outcome - I do think there is a difference if you factor in ‘metastasis free’ survival.
Two men may both live 15 years after treatment, but the addition of ADT ‘could’ make those 15 years event free, while not adding ADT might lead to recurrence or worse, metastasis and all the treatment that goes with it.
Six months of Orgovyx (not Lupron!) is totally do-able and only mildly annoying if you follow a physical exercise regimen of cardio and weight training.
I feel, personally, that it is a small price to pay for that added measure of success. Even Artera AI only has the knowledge that we’ve gathered SO FAR; who knows what gene on that humongous DNA chain will be discovered down the road, showing a peculiar mutation which responds favorably to ADT?
Just my thoughts sculpted by the saying ‘We don’t know what we don’t know’. Best,
Phil